KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Intangibles: 2019-2021

Historic Intangibles for Royalty Pharma (RPRX) over the last 2 years, with Dec 2021 value amounting to $5.7 million.

  • Royalty Pharma's Intangibles fell 80.22% to $5.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $5.7 million, marking a year-over-year decrease of 80.22%. This contributed to the annual value of $5.7 million for FY2021, which is 80.22% down from last year.
  • Latest data reveals that Royalty Pharma reported Intangibles of $5.7 million as of Q4 2021, which was down 50.55% from $11.5 million recorded in Q3 2021.
  • In the past 5 years, Royalty Pharma's Intangibles registered a high of $51.7 million during Q4 2019, and its lowest value of $5.7 million during Q4 2021.
  • Moreover, its 3-year median value for Intangibles was $25.8 million (2020), whereas its average is $26.6 million.
  • Data for Royalty Pharma's Intangibles shows a maximum YoY plummeted of 80.22% (in 2021) over the last 5 years.
  • Quarterly analysis of 3 years shows Royalty Pharma's Intangibles stood at $51.7 million in 2019, then tumbled by 44.58% to $28.7 million in 2020, then plummeted by 80.22% to $5.7 million in 2021.
  • Its last three reported values are $5.7 million in Q4 2021, $11.5 million for Q3 2021, and $17.3 million during Q2 2021.